ISNTD d3 2024
Drug discovery, development & diagnostics
for neglected tropical diseases
Online
27-28th February 2024
#beatNTDs
Introduction
"50 down, 50 to go". 50 countries have eliminated at least one Neglected Tropical Disease, half way to the milestone of 100 countries achieving this goal by 2030.
ISNTD d³ 2024 takes a closer look at how progress in drug discovery and diagnostics in the field of Neglected Tropical Diseases is critical is supporting this ambitious target, and shares some of the recent updates and challenges in the pipeline for drugs and diagnostics for NTDs. This series of talks will address the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development as well as diagnostics and surveillance opportunities.
This year, against the backdrop of 50 countries having eliminated one or more neglected tropical diseases, ISNTD d³ will shine a spotlight on the tools, progress and needs to ensure the goal of 100 countries reaching elimination by 2030 comes into reach.
Presentations & panel discussions will run on both days, and partnership meetings can be arranged throughout the day.
Please contact comparetm@isntd.org for further details and any questions.
Programme
DRUG DISCOVERY & DEVELOPMENT
ISNTD d3 2024: DAY 1
27 FEB 2024
10.00-11.30 UTC
From pipeline to neglected patients: overcoming challenges in drug discovery for NTDs
Evaluating Care and Management of Individuals Impacted by chronic manifestations of NTDs
Dr Lorraine Pfavayi (Postdoctoral Research Associate, University of Edinburgh)
Short-course combination treatment for experimental chronic Chagas disease
Dr Manu de Rycker (Head of Translational Parasitology and Portfolio Leader for Kinetoplastid Drug Discovery at the Drug Discovery Unit, University of Dundee)
Identifying novel snake venom metalloproteinase toxin inhibitors
Dr Rachel Clare (Department of Tropical Disease Biology, Centre for Snakebite Research and Interventions, Liverpool School of Tropical Medicine)
Repurposing of Tuberculosis drug candidates for the treatment of Mycobacterium ulcerans disease
Dr Louisa Warryn (Swiss Tropical and Public Health Institute)
Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities
Dr Exequiel Porta (Research Fellow in Chemistry, UCL School of Pharmacy, University College London)
11.45-13.15 UTC
Spotlight on sleeping sickness: a safer treatment to accelerate elimination
Dr Gerardo Priotto (Medical Officer, World Health Organization)
Dr Philippe Neau ( Head of Neglected Tropical Diseases, Foundation S, the Sanofi Collective)
Dr Wilfried Mutombo Kalonji (Regional Head Of Clinical Operations, Drugs for Neglected Diseases Initiative)
13.30-15.00 UTC
Paediatric advances in neglected tropical diseases treatments
Paediatric drug optimization for neglected tropical diseases: outcomes and progress
Dr Tiziana Masini (World Health Organization (Global Accelerator for Paediatric formulations, GAP-f)
Arpraziquantel to treat schistosomiasis in preschool-aged children
Dr Beatrice Greco (Head of R&D and Access, Merck Global Health Institute)
Ivermectin safety in small children
Dr Kevin Kobylinski (Honorary Visiting Research Fellow, MORU Mahidol Oxford Tropical Medicine Research Unit)
Oral Amphotericin B and paediatric challenges in leishmaniasis treatment
Prof Kishor Wasan (Neglected Global Diseases Initiative, University of British Columbia)
DIAGNOSTICS FOR NEGLECTED TROPICAL DISEASES
ISNTD d3 2024: DAY 2
28 FEB 2024
10.00-11.30 UTC
Technology and tools in Neglected Tropical Diseases diagnostics
Is self-testing the next paradigm for diagnostics?
Dr Shrikant Pawar (Mylab Discovery Solutions)
Near-infrared spectroscopy and machine learning algorithms for rapid and non-invasive detection of Trichuris
Dr Maggy Sikulu-Lord (Centre for Animal Science, University of Queensland)
Smart optical diagnostics for schistosomiasis and intestinal helminth infections
Dr Prosper Oyibo (Delft Center for Systems and Control, Delft University of Technology)
Diagnosing visceral leishmaniasis at the point of need: the IT LEISH Individual Rapid Test
Dr Emily Adams (VP Global Health & Business Development, Global Access Diagnostics)
Molecular diagnostics for neglected tropical diseases
Dr Andy Wende (Xpedite Diagnostics)
11.45-13.15 UTC
Novel diagnostics: neglected tropical diseases surveillance to elimination
Molecular diagnosis of intestinal schistosomiasis: An overview of current protocols and what is needed, highlighted using data from a S. mansoni and S. haematobium co-endemic area
John Archer (Natural History Museum, London and Liverpool School of Tropical Medicine)
Dried Blood Spots (DBS): A suitable alternative to using whole blood samples for diagnostic testing of visceral leishmaniasis in the post-elimination era
Md. Abu Rahat (Research Officer, International Centre for Diarrhoeal Disease Research, Bangladesh, icddr,b)
Coupling ELISA to smartphones for POCT of chronic and congenital Chagas disease
Dr Federico Schaumburg (Instituto de Desarrollo Tecnológico para la Industria Química, INTEC CONICET-UNL, Argentina)
Sensitivity and specificity of human point-of-care circulating cathodic antigen (POC-CCA) test in African livestock for rapid diagnosis of schistosomiasis: A Bayesian latent class analysis
Dr Beatriz Calvo-Urbano (Royal Veterinary College & Imperial College Faculty of Medicine)
13.30-15.00 UTC
The challenges of febrile illnesses diagnosis
Challenges of acute febrile illness diagnosis in a national infectious diseases center in Rio de Janeiro
Dr Clarisse da Silveira Bressan (Acute Febrile Illnesses Service, Oswaldo Cruz Foundation, Rio de Janeiro)
Perceptions and priorities for the development of multiplex rapid diagnostic tests for acute non-malarial fever in rural South and Southeast Asia
Dr Chris Chew (Mahidol Oxford Tropical Medicine Research Unit, Thailand & University of Queensland)
A comprehensive review of dengue with a focus on emerging solutions for precision and timely detection
Harvinder Kour Khera (Tata Institute for Genetics and Society, Bangalore Life Science Cluster, BLiSC)
Bringing high-quality molecular diagnostics to all
Seth Egan (Co-Diagnostics)